| Title: |
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis |
| Authors: |
Simmonds, Mark; Walton, Matthew; Hodgson, Rob; Llewellyn, Alexis; Walker, Ruth; Fulbright, Helen; Bojke, Laura; Stewart, Lesley; Dias, Sofia; Rush, Thomas; Lawrenson, John; Peto, Tunde; Steel, David |
| Source: |
Simmonds, M, Walton, M, Hodgson, R, Llewellyn, A, Walker, R, Fulbright, H, Bojke, L, Stewart, L, Dias, S, Rush, T, Lawrenson, J, Peto, T & Steel, D 2025, 'Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis', Health Technology Assessment, vol. 29, no. 23. https://doi.org/10.3310/KRWP1264 |
| Publication Year: |
2025 |
| Collection: |
Queen's University Belfast: Research Portal |
| Subject Terms: |
Cost-effectiveness; diabetic; systematic review; anti-VEGF; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being |
| Description: |
Background Diabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of macular oedema, vitreous haemorrhage or other complications. Panretinal photocoagulation is the primary treatment for proliferative retinopathy. Anti-vascular endothelial growth factor drugs are used to treat various eye conditions and may be beneficial for people with proliferative or non-proliferative retinopathy. Methods The Anti-VEGF In Diabetes project sought to investigate the clinical and cost-effectiveness of using anti-vascular endothelial growth factor to prevent retinopathy progression when compared to panretinal photocoagulation or no treatment. A systematic review with network meta-analysis of randomised controlled trials of anti-vascular endothelial growth factor (alone or in combination with panretinal photocoagulation) to treat retinopathy was conducted. The database searches were updated in May 2023. Individual participant data from larger trials were sought. A systematic review of non-randomised studies was performed. Existing cost-effectiveness analyses were reviewed, and a new economic model was developed, informed by the individual participant data meta-analysis. The model also estimated the value of undertaking further research to resolve decision uncertainty. Results The review found that anti-vascular endothelial growth factors produced a slight, and not clinically meaningful, benefit over panretinal photocoagulation in best corrected visual acuity, after 1 year of follow-up in people with proliferative retinopathy (mean difference of 4.5 ETDRS letters; 95% credible interval −0.7 to 8.2). There was no evidence of a difference in effectiveness among the different anti-vascular endothelial growth factors. The benefit of anti-vascular endothelial growth factor appears to decline over time. Anti-vascular endothelial growth factor therapy may be more effective in people with poorer initial visual acuity. Anti-vascular endothelial growth factor had no impact on vision in people with ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
1366-5278; 2046-4924 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40347224; info:eu-repo/semantics/altIdentifier/pissn/1366-5278; info:eu-repo/semantics/altIdentifier/eissn/2046-4924 |
| DOI: |
10.3310/KRWP1264 |
| Availability: |
https://pure.qub.ac.uk/en/publications/192e168b-395d-4a1b-a7c2-6c9702cea1ca; https://doi.org/10.3310/KRWP1264; https://pureadmin.qub.ac.uk/ws/files/667304163/antiiiiiii.pdf |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.13ED2BFC |
| Database: |
BASE |